Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03447262 · ClinicalTrials.gov registry record · Phase 3
A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy
A Phase 3 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Terminated
- Registry status
- Phase 3
- Development phase
- 484
- Enrollment target
NCT03447262 is a Phase 3 study that was terminated before completion, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 484 participants.
The verdict
NCT03447262, a Phase 3 study, was terminated before completion, sponsored by Vertex Pharmaceuticals Incorporated.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 484 participants
- Enrollment target
Study Summary
This study will evaluate the long-term safety and tolerability of VX-659 in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are homozygous or heterozygous for the F508del mutation.
Interventions
- DRUG IVA
- DRUG VX-659/TEZ/IVA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 484 participants |
| Start Date | 2018-07-13 |
| Est. Completion | 2020-09-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03447262
The ClinicalTrials.gov registry entry for NCT03447262 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 484 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which IVA is the first listed.
NCT03447262 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03447262 about?
NCT03447262 is a clinical study titled "A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy". This study will evaluate the long-term safety and tolerability of VX-659 in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are homozygous or heterozygous for the F508del mutation.
What is the current status of trial NCT03447262?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 484 participants. The study started on 2018-07-13. Estimated completion is 2020-09-09.
What interventions are being tested in trial NCT03447262?
The interventions under investigation include: IVA (DRUG), VX-659/TEZ/IVA (DRUG).
Who is sponsoring clinical trial NCT03447262?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.